Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Six common diseases arise from DNA changes, finds new research

Many rare disorders are caused by gene mutation, like sickle cell anemia. Yet until now the underlying genetic cause of more common conditions - for example, rheumatoid arthritis - has evaded scientists for years.

22 Dec 2013

New MRI approach can be important tool for diagnosing, tracking MS progression

New imaging research from Western University (London, Canada) has demonstrated that a magnetic resonance imaging approach called quantitative susceptibility mapping can be an important tool for diagnosing and tracking the progression of Multiple Sclerosis and other neurological diseases.

20 Dec 2013

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

Genzyme, a Sanofi company, announced today that the Australian Therapeutic Goods Administration has approved Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis for patients with active disease defined by clinical or imaging features to slow the accumulation of physical disability and reduce the frequency of clinical relapses.

19 Dec 2013

Viewpoints: New healthcare.gov czar knows something about computer bugs; fears about inadequate drug coverage

Seriously, one has to hope the new guy -- Kurt DelBene, former head of the Microsoft Office Division -- brings only a portion of Microsoft's heritage along with him. Aside from the XBox, the software giant isn't known for great consumer experiences. Its products have been maddeningly complex and notoriously buggy, at least in their early versions. Kind of like HealthCare.gov! (Jon Healey, 12/17).

19 Dec 2013

Merck and CNIO sign agreement to collaborate in area of cancer drug development

The Spanish National Cancer Research Centre (CNIO) and the German chemical and pharmaceutical company Merck today signed an agreement in Madrid to collaborate in the area of cancer drug development.

19 Dec 2013

Deep brain stimulation may have beneficial effect on driving ability for Parkinson's disease patients

Deep brain stimulation may have a beneficial effect on driving ability for people with Parkinson's disease, according to a new study published in the December 18, 2013, online issue of Neurology®, the medical journal of the American Academy of Neurology. Deep brain stimulation uses a surgical implant similar to a pacemaker to send electrical impulses to the brain.

19 Dec 2013

MSCs isolated from MS patients have decreased suppressive function

Multiple sclerosis, an inflammatory autoimmune disease affecting more than one million people worldwide, is caused by an immune reaction to myelin proteins, the proteins that help form the myelin insulating substance around nerves. Demyelination and MS are a consequence of this immune reaction. Bone marrow mesenchymal stem cells have been considered as an important source for cell therapy for autoimmune diseases such as MS because of their immunosuppressive properties.

18 Dec 2013

Merck signs license agreement with CNIO for cancer drug development

Merck Serono, the biopharmaceutical division of Merck, today announced that a license agreement has been signed with the Spanish National Cancer Research Centre in Madrid in the area of cancer drug development. The global agreement will build upon CNIO research discoveries to encourage the development and commercialization of new compounds in the field of oncology.

18 Dec 2013

Octapharma enrolls first patients in GAM-27 Phase II/III clinical trial for relapsing multiple sclerosis

Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis. Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualised relapse rate in patients where first-line treatment is not suitable.

18 Dec 2013

Moderate drinking may bolster our immune system and help fight off infection: Study

Medical science has known for years that people who drink moderate amounts of alcohol actually have a reduced risk of death. In general, they are healthier and have better cardiovascular function that those who don't drink alcohol at all.

17 Dec 2013

Researchers use ATX-Red AR-2 as new imaging agent to illuminate tumors

Researchers from Echelon Biosciences, Inc. and collaborators from the University of Utah report the use of ATX-Red AR-2 as a new imaging agent that effectively illuminates tumors.

17 Dec 2013

Biogen joins with Samsung Bioepis to commercialize anti-TNF biosimilar product candidates in Europe

Biogen Idec (NASDAQ: BIIB) and Samsung Bioepis today announced that through their joint venture, Biogen Idec has exercised its right to enter into an agreement to commercialize anti-TNF biosimilar product candidates in Europe, including biosimilars for widely used therapies to treat conditions such as rheumatoid arthritis and Crohn's disease.

17 Dec 2013

Researchers confirm link between contrast agent and abnormalities on brain MRI

For the first time, researchers have confirmed an association between a common magnetic resonance imaging (MRI) contrast agent and abnormalities on brain MRI, according to a new study published online in the journal Radiology. The new study raises the possibility that a toxic component of the contrast agent may remain in the body long after administration.

17 Dec 2013

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Genzyme, a Sanofi company, announced today that Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis, with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.

13 Dec 2013

Standardized research approaches needed for developing new treatments for neurofibromatosis

As potentially effective new treatments for neurofibromatosis (NF) are developed, standardized research approaches—including outcome measures specific to NF—are needed. The first report from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration has been published as a supplement to Neurology, the Official Journal of the American Academy of Neurology (AAN).

13 Dec 2013

Blows to head may affect the brain's white matter and cognition even without concussion

New research suggests that even in the absence of a concussion, blows to the head during a single season of football or ice hockey may affect the brain's white matter and cognition, or memory and thinking abilities. The study is published in the December 11, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology. White matter is brain tissue that plays an important role in the speed of nerve signals.

12 Dec 2013

Synthetic Biologics prices underwritten public offering of common stock at $1.00 per share

Synthetic Biologics, Inc., a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today the pricing of an underwritten public offering of 11,500,000 shares of common stock at a public offering price of $1.00 per share.

12 Dec 2013

MedImmune, Johns Hopkins University enter into $6.5M research collaboration

MedImmune, AstraZeneca’s global biologics research and development arm, and The Johns Hopkins University today announced they have entered into a five-year, $6.5 million research collaboration.

12 Dec 2013

New study aims to determine prevalence of pediatric chronic fatigue syndrome in Chicago area youth

The prevalence of chronic fatigue syndrome in children and the significant impairment it causes to their physical functioning, school attendance and performance, and extracurricular activities, are at the root of a new Chicago-based study led by DePaul University psychologist Leonard A. Jason.

11 Dec 2013

Experimental compound reduces joint inflammation in animal models of rheumatoid arthritis

An experimental compound synthesized and developed by scientists from the Florida campus of The Scripps Research Institute has the capacity to significantly reduce joint inflammation in animal models of rheumatoid arthritis, an autoimmune disease that affects more than two million Americans.

11 Dec 2013

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Six common diseases arise from DNA changes, finds new research

New MRI approach can be important tool for diagnosing, tracking MS progression

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

Viewpoints: New healthcare.gov czar knows something about computer bugs; fears about inadequate drug coverage

Merck and CNIO sign agreement to collaborate in area of cancer drug development

Deep brain stimulation may have beneficial effect on driving ability for Parkinson's disease patients

MSCs isolated from MS patients have decreased suppressive function

Merck signs license agreement with CNIO for cancer drug development

Octapharma enrolls first patients in GAM-27 Phase II/III clinical trial for relapsing multiple sclerosis

Moderate drinking may bolster our immune system and help fight off infection: Study

Researchers use ATX-Red AR-2 as new imaging agent to illuminate tumors

Biogen joins with Samsung Bioepis to commercialize anti-TNF biosimilar product candidates in Europe

Researchers confirm link between contrast agent and abnormalities on brain MRI

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Standardized research approaches needed for developing new treatments for neurofibromatosis

Blows to head may affect the brain's white matter and cognition even without concussion

Synthetic Biologics prices underwritten public offering of common stock at $1.00 per share

MedImmune, Johns Hopkins University enter into $6.5M research collaboration

New study aims to determine prevalence of pediatric chronic fatigue syndrome in Chicago area youth

Experimental compound reduces joint inflammation in animal models of rheumatoid arthritis

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in